40% return in just 2 days. On Monday, it hit the upper circuit with a 20% rise. On Tuesday too, this stock jumped nearly 15%. Why is there such a surge in pharma company Cohance Lifesciences' stock?
According to multiple reports, a particular individual joining this company is one of the main reasons behind the stock price increase. This stock closed at ₹360 on Friday. Since then, by Tuesday, this stock's price touched ₹514.90. It has since declined slightly to ₹497.
Also Read | After 8% fall, is Paytm stock a good buy? Here’s what experts say
Appointment of industry veteran sparks optimism
Umang Vohra has joined as the company's Chairman and Group CEO. Positive momentum has been seen in this stock's price since then. He previously handled responsibilities at Cipla. He is one of the well-known faces in India's pharmaceutical manufacturing industry. Earlier, from 2016 to March 31, 2026, he was the Managing Director and Global CEO of Cipla. Umang Vohra played a major role in determining that company's business direction.
Experts believe that by appointing Umang Vohra, Cohance Lifesciences wants to expand business in the high-value segment. The company currently works in Contract Development and Manufacturing (CDMO), which is considered the fastest-growing area in the pharma sector. Along with this, the company has set goals to expand business in multiple other sectors including more complex chemicals and antibody drug conjugates.
Also Read | Oracle layoffs in India: Pay, benefits and conditions explained
Experts believe there is confidence in Umang Vohra behind the stock price increase. It is believed that under his leadership, this company will get more international contracts, and business scope and profits will increase.
{News Ei Samay does not provide investment advice anywhere. Investment and trading in the share market or any field involve risk. Proper study and expert advice are recommended beforehand. This news is published for educational and awareness purposes.}
